861 completed, 253 terminated, 230 recruiting, 220 unknown. 875 Phase 2, 677 Phase 1, 184 Phase 3, 111 Not applicable, 22 Early Phase 1.
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
Showing 20 of 1835. Sign in to see all of them.
Lymphoma, Follicular (772) · Lymphoma, Non-Hodgkin (728) · Lymphoma, Mantle-Cell (706) · Lymphoma (635) · Leukemia, Lymphocytic, Chronic, B-Cell (596) · Burkitt Lymphoma (573) · Lymphoma, B-Cell, Marginal Zone (555) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (502) · Lymphoma, Large-Cell, Immunoblastic (480) · Hodgkin Disease (400) · Multiple Myeloma (290) · Lymphoma, T-Cell, Cutaneous (270) · Waldenstrom Macroglobulinemia (268) · Lymphoma, Large-Cell, Anaplastic (262)
Hemic and Lymphatic Diseases (1835) · Neoplasms by Histologic Type (1823) · Immune System Diseases (1819) · Immunoproliferative Disorders (1815) · Lymphatic Diseases (1815) · Lymphoproliferative Disorders (1786) · Neoplasms (1721) · Lymphoma, B-Cell (1679) · Lymphoma (1200) · Lymphoma, Non-Hodgkin (1107) · Pathological Conditions, Signs and Symptoms (753) · Pathologic Processes (750) · Hematologic Diseases (746) · Disease Attributes (734) · Leukemia, Lymphoid (678)
Rituximab (425) · Cyclophosphamide (357) · Prednisone (178) · Vincristine (178) · Doxorubicin (173) · Etoposide (162) · Peripheral Blood Stem Cell Transplantation (115) · Filgrastim (108) · Lenalidomide (98) · fludarabine phosphate (96) · Cytarabine (83) · Radiotherapy (81) · Gemcitabine (77) · Melphalan (67) · Mycophenolic Acid (64)
National Cancer Institute (NCI) (123) · Fred Hutchinson Cancer Center (67) · Memorial Sloan Kettering Cancer Center (40) · City of Hope Medical Center (38) · Ruijin Hospital (35) · M.D. Anderson Cancer Center (30) · Case Comprehensive Cancer Center (27) · Mayo Clinic (26) · Novartis Pharmaceuticals (26) · Hoffmann-La Roche (24) · Jonsson Comprehensive Cancer Center (20) · Fondazione Italiana Linfomi - ETS (19) · Masonic Cancer Center, University of Minnesota (19) · Northwestern University (18) · Roswell Park Cancer Institute (17)
United States (1116) · China (294) · France (175) · Italy (164) · United Kingdom (127) · Spain (126) · Germany (107) · Canada (104) · South Korea (96) · Australia (87) · Belgium (77) · Poland (64) · Israel (54) · Japan (52) · Czechia (51)
Ajay Gopal (11) · Brenda Sandmaier (8) · Christos E. Emmanouilides, MD (6) · Corinne Haioun, MD (6) · Craig Moskowitz, MD (6) · Julie M Vose, MD (6)
PMID 34515338, PMID 32499241, PMID 26373676, PMID 27282998, PMID 39319495, PMID 40802906, PMID 23753028, PMID 34310745, PMID 34398557, PMID 39563886, PMID 11807147, PMID 16449523, PMID 16648042, PMID 16754935, PMID 17242396, PMID 19949018, PMID 20028764, PMID 20548096, PMID 20660832, PMID 21482186, PMID 21527516, PMID 22002018, PMID 22337718, PMID 23834234, PMID 24224624, PMID 24862638, PMID 30125215, PMID 30620669, PMID 30770362, PMID 31527168, PMID 32589977, PMID 32817282, PMID 33288485, PMID 34493319, PMID 34634256, PMID 34780623, PMID 35244756, PMID 35337365, PMID 35674661, PMID 35710733, PMID 36375120, PMID 37369099, PMID 38635762, PMID 38775302, PMID 42699559, PMID 7477169, PMID 10552943, PMID 10632319, PMID 10673703, PMID 10764422
P30CA015704 (27), P30CA033572 (27), P30CA043703 (21), U10CA032102 (20), 2023 (19), P30CA015083 (17), 2016 (15), 2015 (13), P30CA006973 (13), P30CA022453 (13), 2017 (12), P30CA036727 (11), 2014 (10), P30CA072720 (10), P30CA016672 (9)